Summa Health System

Biomendics, LLC

Kent State University

Ic-Medtech Corporation

James M Jamison

Chun-che Tsai

Jack L Summers

Thomas M Miller

Karen M McGuire

Richard Albert Mostardi

Deborah R Neal

Michael John Askew

Karen M Mcguire

Mark William Kovacik

Jackie L Summers

Jacques Gilloteaux

Henryk S Taper

Mark Willam Kovacik

Chun-Che Tsai

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):

Formulation and process for modulating wound healing

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I):  Rto Rare independent substituents at any available position of the phenyl rings, preferably at 3, 3', 4, 4&#x2032;, and/or 5, 5&#x2032;; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be &#x2265;1. Each Rto Ris independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): 

Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant

The combination of compounds of the hydroxytolan family with ascorbate plus naphthoquinone (Vitamin K3; VK3), or a quinone or semiquinone analogue of VK3, kill tumor cells, inhibit tumor growth and development, and treat cancer in subjects in need thereof.

Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer

Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of 'MgVC') and Vitamin K3 or (VK3) or a quinone and semiquinone analogue of VK3, are used in methods for killing or inhibiting the growth of tumor or cancer cells or preneoplastic cells in a subject, or for treating cancer in a subject in need of such treatment.

Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone

A combination of Vitamin C and a quinone used as a supplemental treatment for a cancer patient. The combination may be administered before, during and after the patient undergoes a conventional cancer treatment protocol. The combination may be administered orally, intravenously, or intraperitoneally. Oral administration may be in the form of capsules containing a predetermined ratio of Vitamin C to Vitamin K. The supplemental treatment is effective to inhibit metastases of cancer cells and inhibit tumor growth. The ratio of Vitamin C to Vitamin Kis in the range of about 50 to 1 to about 250 to 1. A method for evaluating the effectiveness of the supplemental treatment includes monitoring the patient's serum DNase activity throughout the course of treatment.

Growing community of inventors

Stow, OH, United States of America

James M Jamison